Table 2.
Cost-effectiveness and cost-utility analyses
| Analysis | Incremental costs (95% CI), € | Incremental effects (95% CI) | Mean ICER, € | Distribution of cost-effectiveness plane | |||
|---|---|---|---|---|---|---|---|
| North-east quadrant, % | South-east quadrant, % dominant | South-west quadrant, % | North-west quadrant, % inferior | ||||
| PCT+AD (n = 71) versus antidepressants only (n = 79) | |||||||
| Cost-effectiveness, depression-free days | −3409 (−3458 to −3360) | 34.1 (33.5 to 34.7) | Dominant | 1.9 | 93.1 | 4.5 | 0.4 |
| Cost-utility, QALYs | −3409 (−3458 to −3360) | −0.018 (−0.019 to −0.017) | 184.912 saved per QALY lost | 0.1 | 29.9 | 67.8 | 2.2 |
| Antidepressants only (n = 79) versus PCT/−AD (n = 59) | |||||||
| Cost-effectiveness, depression-free days | −3015 (−3084 to −2947) | 21.0 (20.2 to 21.7) | Dominant | 7.4 | 72.9 | 16.8 | 3.0 |
| Cost-utility, QALYs | −3015 (−3084 to −2947) | 0.051 (0.050 to 0.053) | Dominant | 7.8 | 80.8 | 8.9 | 2.6 |
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; PCT+AD, preventive cognitive therapy and antidepressants; PCT/−AD, preventive cognitive therapy with guided tapering of antidepressants.